Loading…
Hong Kong-listed healthcare/nursing services company; specific service line not confirmed with confidence.
Hong Kong-listed healthcare/nursing services company; specific service line not confirmed with confidence.
Moat: none
Headquarters: Hong Kong · Employees: 467
Size Fameglow (3774.HK) is a Hong Kong Health Care company (Medical/Nursing Services) with a market value of $3.19B, the 328th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$30.58 on 6 Nov 2026.
Growth Revenue grew 35.5% over the last twelve months (peer median +5.0%); the operating margin is 11.1% (peer median 8.2%).
Valuation It trades at 42.5× enterprise value to sales against a peer median of 2.2× (most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is +48%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 20.0 points above its cost of capital (5.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$590M | HK$590M | HK$435M | HK$299M | HK$228M |
| Revenue growth | — | +35% | +45% | +32% | — |
| Gross profit | HK$219M | HK$218M | HK$170M | HK$122M | HK$78.7M |
| EBITDA | HK$146M | HK$146M | HK$114M | HK$90.6M | HK$64.3M |
| Net income | HK$54.6M | HK$54.6M | HK$45.7M | HK$40.8M | HK$16.4M |
| Free cash flow | n/a | HK$45.1M | HK$26.2M | HK$18.3M | HK$38.1M |
| Capital expenditure | n/a | HK$68.1M | HK$53.4M | HK$13.5M | HK$32.2M |
| Total debt | n/a | HK$119M | HK$92.4M | HK$45.5M | HK$66.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3774.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.5% | +8.7% | 7th highest of 21 |
| Distance from 52-week high | -33.1% | -13.0% | 4th lowest of 21 |
| Revenue growth (TTM) | +35.5% | +5.0% | 2nd highest of 21 |
| Operating margin | 11.1% | 8.2% | 7th highest of 21 |
| EV / Sales | 42.5× | 2.2× | most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 48.8% | 17.1% | 2nd most demanding of 17 |
| Growth delivered (Del g) | +48.4% | +11.0% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | +0.4 pp | +3.3 pp | 7th least demanding of 17 |
| ROIC minus cost of capital | +20.0 pp | +0.3 pp | 2nd highest of 20 |
| Net debt / EBITDA | 0.1× | 2.3× | 5th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fameglow 3774.HK | Hong Kong | $3.19B | n/a | +36% | 11% | 42.5× | 48.8% | +48.4% |
| Acadia Healthcare ACHC | United States | $3.44B | +47% | +4% | 10% | 1.8× | n/a | n/a |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.50B | +26% | +17% | 24% | 10.4× | 32.2% | +11.8% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 2.4× | 5.8% | +5.7% |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 1.6× | 13.4% | +10.2% |
| Medicover MCOV-B.ST | Sweden | $4.14B | +36% | +6% | 7% | 2.1× | 20.8% | +20.2% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 1.3× | -4.5% | +2.0% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 1.5× | 4.9% | +13.2% |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 2.5× | 21.6% | +14.6% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 3.2× | n/a | n/a |
| Option Care Health OPCH | United States | $4.74B | +54% | +4% | 6% | 1.0× | 1.5% | +13.2% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 2.0× | 6.7% | -6.1% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 1.5× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | 1.6× | 21.3% | +8.5% |
| Lifestance Health LFST | United States | $5.26B | +79% | +20% | 5% | 3.5× | 37.8% | +30.4% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 0.3× | n/a | n/a |
| BillionToOne BLLN | United States | $5.38B | +54% | +90% | 11% | 12.5× | 26.8% | +90.1% |
| Concentra Group Holdings Parent CON | United States | $5.38B | +75% | +14% | 17% | 3.2× | 3.9% | +7.9% |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 4.2× | n/a | n/a |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 7.4× | 41.9% | +26.9% |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 2.4× | 56.0% | +8.9% |